{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:09Z","timestamp":1792783329561,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","award":["PW2023A-11"],"award-info":[{"award-number":["PW2023A-11"]}],"id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Young2024-0414"],"award-info":[{"award-number":["Y-Young2024-0414"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing InnoCare Pharma Tech Co., Ltd.","id":[{"id":"https:\/\/ror.org\/02ytzht62","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01243-y","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T04:16:55Z","timestamp":1785644215000},"page":"735-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGF\/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials"],"prefix":"10.1007","volume":"21","author":[{"given":"Liqiong","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sichen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1813-9815","authenticated-orcid":false,"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"key":"1243_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1665019","volume":"15","author":"H Sun","year":"2050","unstructured":"Sun H, Yu M, An Z, Liang F, Sun B, Liu Y, et al. Global burden of head and neck cancer: epidemiological transitions, inequities, and projections to 2050. Front Oncol. 2050;15:1665019. https:\/\/doi.org\/10.3389\/fonc.2025.1665019.","journal-title":"Front Oncol"},{"key":"1243_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1243_CR3","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","volume":"398","author":"MD Mody","year":"2021","unstructured":"Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398:2289\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(21)01550-6.","journal-title":"Lancet"},{"key":"1243_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2022","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2022;4:47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J Natl Cancer Cent"},{"key":"1243_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jama.2025.21733","volume":"335","author":"LA Dunn","year":"2026","unstructured":"Dunn LA, Ho AL, Pfister DG. Head and neck cancer: a review. JAMA. 2026;335:531\u201341. https:\/\/doi.org\/10.1001\/jama.2025.21733.","journal-title":"JAMA"},{"key":"1243_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","volume":"77","author":"KH Au","year":"2018","unstructured":"Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018;77:16\u201321. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.12.004.","journal-title":"Oral Oncol"},{"key":"1243_CR7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro JG, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048). Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"1243_CR8","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"key":"1243_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/CCO.0000000000001211","volume":"38","author":"JA Vuille","year":"2026","unstructured":"Vuille JA, Szturz P. Recent highlights and breakthroughs in immunotherapy for head and neck cancers. Curr Opin Oncol. 2026;38:201\u201311. https:\/\/doi.org\/10.1097\/CCO.0000000000001211.","journal-title":"Curr Opin Oncol"},{"issue":"20","key":"1243_CR10","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA. 2023;330(20):1961\u201370. https:\/\/doi.org\/10.1001\/jama.2023.20181.","journal-title":"JAMA"},{"key":"1243_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17233817","volume":"17","author":"FF Abraham","year":"2025","unstructured":"Abraham FF, Julian R. Emerging and investigational systemic therapies in recurrent\/metastatic head and neck cancer after progression on immunotherapy. Cancers (Basel). 2025;17:3817. https:\/\/doi.org\/10.3390\/cancers17233817.","journal-title":"Cancers (Basel)"},{"key":"1243_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102938","volume":"136","author":"M Tahara","year":"2025","unstructured":"Tahara M, Lim DW, Keam B, Ma B, Zhang L, Wang C, et al. Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1\/PD-L1 immunotherapy. Cancer Treat Rev. 2025;136:102938. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102938.","journal-title":"Cancer Treat Rev"},{"key":"1243_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01297-0","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther. 2023;8:31. https:\/\/doi.org\/10.1038\/s41392-022-01297-0.","journal-title":"Signal Transduct Target Ther"},{"key":"1243_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","volume":"21","author":"M Katoh","year":"2024","unstructured":"Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat Rev Clin Oncol. 2024;21:312\u201329. https:\/\/doi.org\/10.1038\/s41571-024-00869-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"1243_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/PPO.0000000000000615","volume":"28","author":"Z Wang","year":"2022","unstructured":"Wang Z, Anderson KS. Therapeutic targeting of FGFR signaling in head and neck cancer. Cancer J. 2022;28:354\u201362. https:\/\/doi.org\/10.1097\/PPO.0000000000000615.","journal-title":"Cancer J"},{"key":"1243_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","volume":"39","author":"C Huang","year":"2021","unstructured":"Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021;39:361-79.e16. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.007.","journal-title":"Cancer Cell"},{"key":"1243_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","volume":"21","author":"TY Seiwert","year":"2015","unstructured":"Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21:632\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3310.","journal-title":"Clin Cancer Res"},{"key":"1243_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/path.4575","volume":"237","author":"AKF Lo","year":"2015","unstructured":"Lo AKF, Dawson CW, Young LS, Ko CW, Hau PM, Lo KW. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells. J Pathol. 2015;237:238\u201348. https:\/\/doi.org\/10.1002\/path.4575.","journal-title":"J Pathol"},{"key":"1243_CR19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.4161\/15384047.2014.961874","volume":"15","author":"L Yuan","year":"2014","unstructured":"Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q, Zeng MS. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer Biol Ther. 2014;15:1613\u201321. https:\/\/doi.org\/10.4161\/15384047.2014.961874.","journal-title":"Cancer Biol Ther"},{"key":"1243_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251202","volume":"16","author":"Y Hu","year":"2021","unstructured":"Hu Y, Ai LS, Zhou LQ. Prognostic value of FGFR1 expression and amplification in patients with HNSCC: a systematic review and meta-analysis. PLoS ONE. 2021;16:e0251202. https:\/\/doi.org\/10.1371\/journal.pone.0251202.","journal-title":"PLoS ONE"},{"key":"1243_CR21","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-15-1874","volume":"22","author":"K Koole","year":"2016","unstructured":"Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, et al. FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res. 2016;22:3884\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1874.","journal-title":"Clin Cancer Res"},{"key":"1243_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-015-0374-9","volume":"11","author":"NA Ipenburg","year":"2016","unstructured":"Ipenburg NA, Koole K, Liem KS, van Kempen PM, Koole R, van Diest PJ, et al. Fibroblast growth factor receptor family members as prognostic biomarkers in head and neck squamous cell carcinoma: a systematic review. Target Oncol. 2016;11:17\u201327. https:\/\/doi.org\/10.1007\/s11523-015-0374-9.","journal-title":"Target Oncol"},{"key":"1243_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2017.12.016","volume":"91","author":"C Dubot","year":"2018","unstructured":"Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali H, Schnitzler A, et al. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur J Cancer. 2018;91:47\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2017.12.016.","journal-title":"Eur J Cancer"},{"key":"1243_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71235","volume":"14","author":"C Jiang","year":"2025","unstructured":"Jiang C, Dou S, Wang Y, Jiang W, Ye L, Li R, et al. Prognosis and failure patterns of 11q13 amplified local advanced squamous cell carcinoma of the head and neck. Cancer Med. 2025;14:e71235. https:\/\/doi.org\/10.1002\/cam4.71235.","journal-title":"Cancer Med"},{"key":"1243_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.813732","volume":"13","author":"S Dou","year":"2022","unstructured":"Dou S, Zhang L, Wang C, Yao Y, Jiang W, Ye L, et al. EGFR mutation and 11q13 amplification are potential predictive biomarkers for immunotherapy in head and neck squamous cell carcinoma. Front Immunol. 2022;13:813732. https:\/\/doi.org\/10.3389\/fimmu.2022.813732.","journal-title":"Front Immunol"},{"key":"1243_CR26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, et al. Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24:925\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(23)00275-9.","journal-title":"Lancet Oncol"},{"key":"1243_CR27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti NO, Gutierrez M, Smith DC, F\u00e9liz L, Lihou CF, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33:522\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.001.","journal-title":"Ann Oncol"},{"issue":"Suppl. 15","key":"1243_CR28","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1200\/JCO.2021.39.15_suppl.4092","volume":"39","author":"Y Guo","year":"2021","unstructured":"Guo Y, Yuan C, Ying J, Zhu X, Luan G, Zhang B, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. J Clin Oncol. 2021;39(Suppl. 15):4092. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4092.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 16","key":"1243_CR29","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1200\/JCO.2022.40.16_suppl.6039","volume":"40","author":"Y Guo","year":"2022","unstructured":"Guo Y, Li Q, Tang W, Lin F, Xue J, Xue L, et al. Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF\/FGFR gene aberrations. J Clin Oncol. 2022;40(Suppl. 16):6039. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.6039.","journal-title":"J Clin Oncol"},{"key":"1243_CR30","doi-asserted-by":"publisher","first-page":"PO.18.00100","DOI":"10.1200\/PO.18.00100","volume":"2","author":"EI Dumbrava","year":"2018","unstructured":"Dumbrava EI, Alfattal R, Miller VA, Tsimberidou AM. Complete response to a fibroblast growth factor receptor inhibitor in a patient with head and neck squamous cell carcinoma harboring FGF amplifications. JCO Precis Oncol. 2018;2:PO.18.00100. https:\/\/doi.org\/10.1200\/PO.18.00100.","journal-title":"JCO Precis Oncol"},{"issue":"Suppl. 4","key":"1243_CR31","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2023.41.4_suppl.572","volume":"41","author":"Y Guo","year":"2023","unstructured":"Guo Y, Yuan C, Ding W, Gao Y, Zhu X, Ying J, et al. Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: a phase IIa dose-expansion study. J Clin Oncol. 2023;41(Suppl. 4):572. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.572.","journal-title":"J Clin Oncol"},{"key":"1243_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204","volume":"4","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Verstovsek S. Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med. 2023;4:101204. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101204.","journal-title":"Cell Rep Med"},{"key":"1243_CR33","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","volume":"20","author":"M Schuler","year":"2019","unstructured":"Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1454\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(19)30412-7.","journal-title":"Lancet Oncol"},{"key":"1243_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy287.012","author":"M Joerger","year":"2018","unstructured":"Joerger M, Takahashi S, Sayehli CM, Slosarczyk S, Navarro Mendivil A, Cassier PA, et al. Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression. Ann Oncol. 2018. https:\/\/doi.org\/10.1093\/annonc\/mdy287.012.","journal-title":"Ann Oncol"},{"key":"1243_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02167-9","volume":"23","author":"M Peng","year":"2024","unstructured":"Peng M, Deng J, Li X. Clinical advances and challenges in targeting FGF\/FGFR signaling in lung cancer. Mol Cancer. 2024;23:256. https:\/\/doi.org\/10.1186\/s12943-024-02167-9.","journal-title":"Mol Cancer"},{"key":"1243_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100647","volume":"7","author":"Y Uehara","year":"2022","unstructured":"Uehara Y, Ikeda S, Kim KH, Lim HJ, Adashek JJ, Persha HE, et al. Targeting the FGF\/FGFR axis and its co-alteration allies. ESMO Open. 2022;7:100647. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100647.","journal-title":"ESMO Open"},{"key":"1243_CR37","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","volume":"12","author":"Q Wu","year":"2022","unstructured":"Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, et al. EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2022;12:1378\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1168.","journal-title":"Cancer Discov"},{"key":"1243_CR38","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1158\/1078-0432.CCR-20-0232","volume":"27","author":"A Bernat-Peguera","year":"2021","unstructured":"Bernat-Peguera A, Navarro-Ventura J, Lorenzo-Sanz L, da Silva-Diz V, Bosio M, Palomero L, et al. FGFR inhibition overcomes resistance to EGFR-targeted therapy in epithelial-like cutaneous carcinoma. Clin Cancer Res. 2021;27:1491\u2013504. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0232.","journal-title":"Clin Cancer Res"},{"key":"1243_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167940","volume":"1871","author":"M Orsolic","year":"2025","unstructured":"Orsolic M, Diensthuber M, Stover T, Geissler C. Combined inhibition of EGFR and FGFRs with cetuximab and infigratinib showed effectiveness and relevance in proliferation and migration of HNSCC cell lines. Biochim Biophys Acta Mol Basis Dis. 2025;1871:167940. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167940.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1243_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01954-8","volume":"23","author":"F Broghammer","year":"2024","unstructured":"Broghammer F, Korovina I, Gouda M, Celotti M, van Es J, Lange I, et al. Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome. Mol Cancer. 2024;23:39. https:\/\/doi.org\/10.1186\/s12943-024-01954-8.","journal-title":"Mol Cancer"},{"key":"1243_CR41","doi-asserted-by":"publisher","first-page":"2021619","DOI":"10.1080\/2162402X.2021.2021619","volume":"11","author":"M Kono","year":"2022","unstructured":"Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, et al. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. Oncoimmunology. 2022;11:2021619. https:\/\/doi.org\/10.1080\/2162402X.2021.2021619.","journal-title":"Oncoimmunology."},{"key":"1243_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122968","volume":"13","author":"A Kommalapati","year":"2021","unstructured":"Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers (Basel). 2021;13:2968. https:\/\/doi.org\/10.3390\/cancers13122968.","journal-title":"Cancers (Basel)"},{"key":"1243_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 2022;12:402\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0697.","journal-title":"Cancer Discov"},{"key":"1243_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.survophthal.2023.09.007","volume":"69","author":"J Hsu","year":"2024","unstructured":"Hsu J, Francis JH, Ahmad S. Ocular toxicities of fibroblast growth factor receptor inhibitors: a review. Surv Ophthalmol. 2024;69:34\u201341. https:\/\/doi.org\/10.1016\/j.survophthal.2023.09.007.","journal-title":"Surv Ophthalmol"},{"key":"1243_CR45","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jamaophthalmol.2021.3331","volume":"139","author":"JH Francis","year":"2021","unstructured":"Francis JH, Harding JJ, Schram AM, Canestraro J, Haggag-Lindgren D, Heinemann M, et al. Clinical and morphologic characteristics of fibroblast growth factor receptor inhibitor-associated retinopathy. JAMA Ophthalmol. 2021;139:1126\u201330. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.3331.","journal-title":"JAMA Ophthalmol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01243-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01243-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01243-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:52:07Z","timestamp":1790916727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01243-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1243"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01243-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ye Guo reports honoraria or consulting fees from Merck Serono, Roche, MSD, BeOne, AstraZeneca, Bristol Myers Squibb and Johnson & Johnson, outside the submitted work. Wei Zhou and Sichen Li are employees of Beijing InnoCare Pharma Tech Co., Ltd. Liqiong Xue, Guopei Zhu, Peiguo Wang, Kunyu Yang, Yan Sun, Weidong Li, Zhendong Li, Cuihong Jiang, Qingqing Cai, Meiyu Fang, Man Hu and Minghua Ge have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both studies were conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. Study 301 and Study 304 were multicentre trials; the protocols and all amendments received central ethical approval from the lead-site ethics committee, the Ethics Committee of Shanghai East Hospital, School of Medicine, Tongji University (Clinical Trial Review No. 066 [2018] for Study 301 and No. 085 [2021] for Study 304), and were also reviewed and approved by the institutional review board or independent ethics committee at each participating site.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent before enrolment.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during this study are not publicly available because of patient privacy requirements and the proprietary nature of the ongoing clinical programme. Aggregate data supporting the findings are included in this article and its additional file. Individual patient-level data may be made available from the corresponding author upon reasonable request, subject to review and approval by the study investigators and sponsor, and execution of an appropriate data-sharing agreement. Clinical trial results will be posted on ClinicalTrials.gov in accordance with applicable regulations.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YG conceived and designed the study, had full access to all study data, and takes responsibility for the integrity of the data and the accuracy of the analysis. LX, GZ, PW, KY, YS, WL, ZL, CJ, QC, MF, MH, MG, WZ, SL and YG conducted the study and collected data. SL analysed the data. LX and YG drafted the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}